Stock Monitor: Bioverativ Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 22, 2018 / Active-Investors.com has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: VYGR) ("Voyager"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VYGR as the Company's latest news hit the wire. On February 20, 2018, the Company, which is a clinical-stage gene therapy organization, and AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical Company, declared that they have entered into an exclusive global strategic collaboration and option agreement to develop and commercialize vectorized antibodies for the treatment of the Alzheimer's disease and other Tau-related neuro-degenerative diseases. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Bioverativ Inc. (NASDAQ: BIVV), which also belongs to the Healthcare sector as the Company Voyager Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=BIVV
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Voyager Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=VYGR
Limitations in Existing Therapies for Tau-Related Neuro-Degenerative Diseases
In healthy individuals, Tau is an abundant protein in the brain and fosters cellular stability and function. In the diseased brain, altered Tau accumulates, which leads to impaired brain function and neuronal cell loss. The spread of abnormal Tau in the brain also leads to progressive neuro-degeneration and symptom severity.
At present, weekly or bi-weekly infusions of biologic therapies are used for the treatment of neuro-degenerative diseases. However, this current level of therapy allows only a small amount of drug to enter the brain.
Terms of the Collaboration
The collaboration and option agreement between Voyager and AbbVie aims to develop a potential one-time treatment for neuro-degenerative diseases. The alliance brings together AbbVie's monoclonal antibody expertise, global clinical development, and commercial capabilities with Voyager's gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neuro-degenerative diseases. Voyager's gene therapy platform would be used to reduce Tau pathology through the delivery of an AAV vector antibody that encodes the genetic instructions to create anti-Tau antibodies within the brain.
- As per the terms of the agreement, Voyager will execute the research and pre-clinical development of vectorized antibodies directed against Tau. After that, AbbVie may select one or more vectorized antibodies to proceed into IND-enabling studies and clinical development.
- The agreement holds Voyager responsible for the research, IND-enabling, and Phase-1 studies activities and costs.
- Subsequent to the completion of Phase-1 clinical development, AbbVie would have an option to license the vectorized Tau antibody program. Thereafter, AbbVie would lead further clinical development and global commercialization for Tauopathies, including the Alzheimer's disease and other neuro-degenerative diseases.
- It must be noted that the agreement provides Voyager an option to share the costs of clinical development for higher royalty rates.
Financial Considerations
- As per the agreement, Voyager will receive an upfront cash payment of $69 million and potential pre-clinical and Phase-1 option payments of up to $155 million.
- Besides, Voyager is entitled to receive up to $895 million in development and regulatory milestones for each vectorized Tau antibody compound.
- Moreover, Voyager is also eligible to receive tiered royalties on the global commercial net sales of the vectorized antibodies for Tauopathies, including the Alzheimer's disease and other neuro-degenerative diseases.
Collaboration Would Bring Innovative Treatments for Patients with Neuro-Degenerative Diseases
AbbVie's leadership and deep expertise in monoclonal antibody discovery, development, and commercialization, and Voyager's ability to vectorize monoclonal antibodies makes for a natural fit. Steven Paul, M.D., President and Chief Executive Officer (CEO) of Voyager, shared that he is pleased to collaborate with AbbVie to advance its strategy of bringing innovative treatments to patients. Besides, this alliance is also an important advancement in the Company's strategy to leverage its AAV gene therapy platform and programs through partnerships with biopharmaceutical Companies that bring complementary expertise and capabilities, apart from capital.
Likewise, Jim Sullivan, Ph.D., Vice President, Pharmaceutical Discovery at AbbVie, also believes that this collaboration has the potential to address the needs of patients suffering with the Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia.
Stock Performance Snapshot
February 21, 2018 - At Wednesday's closing bell, Voyager Therapeutics' stock surged 15.47%, ending the trading session at $27.32.
Volume traded for the day: 1.20 million shares, which was above the 3-month average volume of 363.26 thousand shares.
Stock performance in the last month – up 35.05%; previous three-month period – up 110.97%; past twelve-month period – up 119.26%; and year-to-date - up 64.58%
After yesterday's close, Voyager Therapeutics' market cap was at $728.90 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
